The role of ANG II and endothelin-1 in exercise-induced diastolic dysfunction in heart failure.
The diastolic dysfunction present at rest in congestive heart failure (CHF) is exacerbated during exercise (Ex). Increases in circulating ANG II and endothelin-1 (ET-1) during Ex may contribute to this response. We assessed the effect of Ex on circulating plasma levels of ANG II and ET-1 and left ventricular (LV) dynamics before and after pacing-induced CHF at rest and during Ex in nine conscious, instrumented dogs. Before CHF, there were modest increases in circulating levels of ANG II (but not ET-1) during Ex. LV diastolic performance was enhanced during Ex with decreases in the time constant of LV relaxation (tau), LV end-systolic volume (V(ES)), and LV minimum pressure with a downward shift of the LV early diastolic portion of the pressure-volume (P-V) loop. This produced an increase in peak LV filling rate without an increase in mean left atrial (LA) pressure. After CHF, the resting values of ANG II and ET-1 were elevated and increased to very high levels during Ex. After CHF, mean LA pressure, tau, and LV minimum pressure were elevated at rest and increased further during Ex. Treatment with L-754,142, a potent ET-1 antagonist, or losartan, an ANG II AT(1)-receptor blocker, decreased these abnormal Ex responses in CHF more effectively than an equally vasodilatory dose of sodium nitroprusside. Combined treatment with both ANG II- and ET-1-receptor blockers was more effective than either agent alone. We conclude that in CHF, circulating ANG II and ET-1 increase to very high levels during Ex and exacerbate the diastolic dysfunction present at rest.
Cardiology Section, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157-1045, USA. ccheng@wfubmc.edu
C P
CP
Cheng
T
T
Ukai
K
K
Onishi
N
N
Ohte
M
M
Suzuki
Z S
ZS
Zhang
H J
HJ
Cheng
H
H
Tachibana
A
A
Igawa
W C
WC
Little
D000081:Acetamides / Q000494:pharmacology; D000804:Angiotensin II / Q000097:blood*; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D016279:Atrial Function, Left / Q000502:physiology; D003971:Diastole / Q000502:physiology*; D004195:Disease Models, Animal; D004285:Dogs; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000097:blood*; D006333:Heart Failure / Q000097:blood / Q000503:physiopathology*; D019808:Losartan / Q000494:pharmacology; D009599:Nitroprusside / Q000494:pharmacology; D005082:Physical Exertion / Q000502:physiology*; D012016:Reference Values; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology; D016277:Ventricular Function, Left / Q000502:physiology*
D000081:Acetamides; D057911:Angiotensin Receptor Antagonists; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; C097296:L 754142; D000804:Angiotensin II; D009599:Nitroprusside; D019808:Losartan